199 interactions · 40 peptides · FDA + PMID cited

Peptide Drug Interactions.

A searchable reference of documented interactions between peptides and prescription medications, supplements, and anesthetic agents. Always check with your prescriber before combining.

62
Major
Avoid or require supervision
87
Moderate
Caution; dose or monitoring
12
Minor
Theoretical or low impact
38
Monitor
Track labs or symptoms
For research and educational use only. This tool summarizes published interaction data. It is not medical advice. Always check with your prescribing physician or pharmacist before combining peptides with prescription medications, supplements, or other substances.
Tirzepatide (Mounjaro / Zepbound) 13 interactions
General anesthesia / deep sedation (preoperative aspiration risk)
Major
Delayed gastric emptying produces retained gastric contents despite standard NPO fasting; rare postmarketing reports of pulmonary aspiration during elective procedures. FDA Mounjaro label §5.x Warnings (added 2024 class labeling). ASA 2023 consensus + 2024 multisociety guidance: consider holding once-weekly tirzepatide one dose (7 days) prior to elective procedures requiring general anesthesia/deep sedation; assess gastric content with point-of-care ultrasound if clinically warranted. PMID: 39550027 (multisociety GLP-1RA perioperative guidance, 2024). Source: FDA Mounjaro PI 2025; ASA Consensus 2023.
Insulin (basal and prandial — glargine, detemir, degludec, lispro, aspart, NPH, regular)
Major
Additive hypoglycemia risk. Tirzepatide augments glucose-dependent insulin secretion while insulin provides exogenous insulin load; combined effect can produce severe hypoglycemia, especially during dose escalation. FDA Mounjaro label §5.4 and §7.1. When initiating tirzepatide, reduce concomitant insulin dose; titrate based on glucose monitoring. Patient education on hypoglycemia signs is required. Source: FDA Mounjaro PI 2025 (215866s039).
Oral hormonal contraceptives (combined and progestin-only ethinyl estradiol / norethindrone / levonorgestrel)
Major
Tirzepatide-delayed gastric emptying reduces absorption of oral contraceptives, especially after the first dose and after each escalation. Contraceptive failure has been reported. FDA Mounjaro label §7.3. Switch to non-oral contraception, OR add a barrier method for 4 weeks after starting tirzepatide AND for 4 weeks after each dose escalation. Non-oral hormonal contraceptives (patch, ring, IUD, implant, injection) are not affected. Source: FDA Mounjaro PI 2025 §7.3.
Other GLP-1 receptor agonists or dual/triple incretin agonists (semaglutide, liraglutide, dulaglutide, exenatide, retatrutide, orforglipron)
Major
Duplicate-therapy. No additional efficacy, additive GI adverse effects, additive aspiration and hypoglycemia risk. FDA Mounjaro label §7.4 — not studied in combination with other GLP-1RAs. Standard of care is single GLP-1RA / incretin agonist at a time. Source: FDA Mounjaro PI 2025 §7.4.
Pramlintide (Symlin) — amylin analogue
Major
Both drugs delay gastric emptying; combination produces additive delay, increased GI adverse events, and additive hypoglycemia when used with insulin. Not studied in combination. Avoid coadministration. Mechanism-based class warning consistent with FDA Mounjaro §7.2 and Symlin PI. Source: FDA Mounjaro PI 2025; Symlin PI.
Sulfonylureas (glipizide, glyburide, glimepiride)
Major
Additive hypoglycemia risk. Sulfonylureas drive glucose-independent insulin secretion; tirzepatide adds glucose-dependent insulinotropic effect plus delayed gastric emptying, prolonging glucose-lowering action. FDA Mounjaro label §5.4 and §7.1. Consider sulfonylurea dose reduction at tirzepatide initiation and at each escalation. Source: FDA Mounjaro PI 2025.
Antibiotics with narrow absorption windows (oral azithromycin, doxycycline) and bisphosphonates (alendronate, risedronate)
Moderate
Delayed gastric emptying may alter absorption rate; bisphosphonates require strict fasting and upright posture for absorption, and gastric retention reduces efficacy. FDA Mounjaro label §7.2 (general oral-absorption warning). Take bisphosphonates per their own labeling (30-60 min before food in upright position); consider monitoring antibiotic efficacy. Source: FDA Mounjaro PI 2025 §7.2.
Drugs causing pancreatitis (DPP-4 inhibitors, valproate, azathioprine, didanosine, pentamidine, high-dose corticosteroids)
Moderate
Additive risk of acute pancreatitis. GLP-1RA class carries a pancreatitis signal (acute pancreatitis reported in SURPASS trials). FDA Mounjaro label §5.3. Use caution; discontinue tirzepatide promptly if pancreatitis is suspected. Source: FDA Mounjaro PI 2025 §5.3.
Meglitinides (repaglinide, nateglinide)
Moderate
Insulin-secretagogue class — additive hypoglycemia by same mechanism as sulfonylureas. FDA Mounjaro label §7.1 (insulin secretagogues as a class). Reduce meglitinide dose at tirzepatide initiation. Source: FDA Mounjaro PI 2025.
Narrow-therapeutic-index oral drugs (warfarin, digoxin, levothyroxine, phenytoin, lithium, theophylline, cyclosporine, tacrolimus)
Moderate
Delayed gastric emptying alters rate (and occasionally extent) of oral absorption. Effect is greatest after the first dose and after each escalation; diminishes with chronic dosing. FDA Mounjaro label §7.2. Monitor patients on oral medications dependent on threshold concentrations for efficacy and those with narrow therapeutic index. Source: FDA Mounjaro PI 2025 §7.2.
Warfarin and other coumarin anticoagulants (acenocoumarol, phenprocoumon)
Moderate
No clinically relevant PK interaction in healthy-volunteer DDI study, but delayed gastric emptying may alter onset of absorption and post-marketing reports of altered INR exist for the GLP-1RA class. FDA Mounjaro label §7.2 — monitor INR more frequently after tirzepatide initiation or dose change in patients on warfarin or other coumarin derivatives. Source: FDA Mounjaro PI 2025 §7.2 and §12.3.
Acetaminophen (paracetamol)
Monitor
Single 5 mg tirzepatide dose decreased acetaminophen Cmax by 50% and delayed Tmax by 1 hour due to delayed gastric emptying. Total exposure (AUC) was not meaningfully changed. Effect attenuates after the first dose. FDA Mounjaro label §12.3 Table on PK effects. Clinical significance is low for routine analgesic dosing but consider delayed onset of effect when rapid relief is needed. Source: FDA Mounjaro PI 2025 §12.3.
Alcohol (ethanol)
Monitor
No formal PK interaction, but additive GI adverse effects (nausea, vomiting) and potential additive hypoglycemia when combined with insulin/sulfonylureas. Heavy alcohol use is a pancreatitis risk factor; tirzepatide carries a pancreatitis precaution. FDA Mounjaro label §5.3 (pancreatitis precaution). Advise patients to limit alcohol intake during therapy. Source: FDA Mounjaro PI 2025 §5.3.
Semaglutide (Ozempic / Wegovy / Rybelsus) 16 interactions
General anesthesia / deep sedation (preoperative aspiration risk)
Major
Delayed gastric emptying produces residual gastric contents despite NPO; rare postmarketing reports of pulmonary aspiration. FDA Wegovy label §5.x and Ozempic label §5.x (class labeling added 2024). ASA 2023 consensus: consider holding once-weekly semaglutide one dose (7 days) prior to elective procedures; once-daily Rybelsus held on day of procedure. Multisociety 2024 update (PMID: 39550027) emphasizes shared decision-making. Source: FDA Ozempic/Wegovy PI 2025; ASA Consensus 2023.
Insulin (basal and prandial)
Major
Additive hypoglycemia risk in patients with type 2 diabetes. Hypoglycemia observed in SUSTAIN trials when semaglutide 0.5 mg and 1 mg combined with insulin. FDA Ozempic and Wegovy labels §5.4 and §7.1. Reduce insulin dose at semaglutide initiation; titrate based on glucose monitoring. Source: FDA Ozempic PI 2025 (209637s035); FDA Wegovy PI 2025 (215256s026).
Other GLP-1 receptor agonists / incretin agonists (tirzepatide, liraglutide, dulaglutide, exenatide, retatrutide, orforglipron)
Major
Duplicate therapy — no additional efficacy, additive GI and aspiration risk. FDA Ozempic / Wegovy labels — not studied in combination. Use one incretin agent at a time. Source: FDA Ozempic PI 2025.
Pramlintide (Symlin)
Major
Additive delayed gastric emptying and additive hypoglycemia when used with insulin. Not studied in combination. Avoid. Mechanism-based class precaution. Source: Symlin PI; FDA Ozempic PI 2025 §7.2.
Sulfonylureas (glipizide, glyburide, glimepiride)
Major
Additive hypoglycemia. Sulfonylureas drive glucose-independent insulin secretion; semaglutide adds glucose-dependent insulinotropic effect plus delayed gastric emptying. FDA Ozempic and Wegovy labels §7.1. Consider sulfonylurea dose reduction at semaglutide initiation. Source: FDA Ozempic PI 2025; Wegovy PI 2025.
Drugs altering gastric pH — PPIs (omeprazole, esomeprazole, pantoprazole), H2 blockers (famotidine, ranitidine), antacids (Rybelsus only)
Moderate
Rybelsus absorption depends on transient gastric pH change from SNAC co-formulation. Omeprazole 40 mg daily increased semaglutide AUC and Cmax modestly in DDI study, but interpretive guidance from label is that no dose adjustment is required. FDA Rybelsus label §12.3. Take Rybelsus per its labeling (empty stomach, ≤120 mL water, then 30-min fast); PPI use does not require dose adjustment but counsel on timing. Source: FDA Rybelsus PI 2025 §12.3.
Drugs causing pancreatitis (valproate, azathioprine, didanosine, pentamidine, high-dose corticosteroids, DPP-4 inhibitors)
Moderate
Additive risk of acute pancreatitis. SUSTAIN and STEP trials reported pancreatitis cases on semaglutide. FDA Ozempic and Wegovy labels §5.3 (pancreatitis precaution). Discontinue semaglutide if pancreatitis suspected. Source: FDA Ozempic PI 2025 §5.3.
Levothyroxine (Rybelsus / oral semaglutide only)
Moderate
Levothyroxine total exposure (AUC) increased 33% (90% CI 125-142%) when coadministered with Rybelsus. Mechanism is altered gastric absorption window related to SNAC co-formulation. FDA Rybelsus label §7.2 and §12.3. Monitor TSH 6-8 weeks after reaching maintenance semaglutide dose; adjust levothyroxine dose as needed. Subcutaneous Ozempic/Wegovy do NOT show this PK effect. Source: FDA Rybelsus PI 2025 (213051s024).
Meglitinides (repaglinide, nateglinide)
Moderate
Same insulin-secretagogue mechanism as sulfonylureas — additive hypoglycemia. FDA Ozempic label §7.1 (insulin secretagogues as a class). Reduce dose at semaglutide initiation. Source: FDA Ozempic PI 2025.
Oral medications generally — narrow therapeutic index (digoxin, phenytoin, lithium, cyclosporine, tacrolimus)
Moderate
Delayed gastric emptying alters rate and occasionally extent of oral absorption. With Rybelsus there is an additional gastric-pH absorption-window effect. FDA Ozempic label §7.2; FDA Rybelsus label §7.2. Monitor patients on narrow-therapeutic-index oral drugs. Rybelsus must be taken at least 30 minutes before any other oral medication, food, or liquid. Source: FDA Rybelsus PI 2025 §2.1, §7.2.
Warfarin and coumarin anticoagulants (warfarin, acenocoumarol, phenprocoumon)
Moderate
Healthy-volunteer DDI study showed no clinically relevant change in warfarin PK, peak concentration, time to peak, or INR. However, postmarketing reports describe decreased INR with concomitant acenocoumarol. FDA Ozempic label §12.3 and §7.2. More frequent INR monitoring may be considered when semaglutide is initiated in patients taking warfarin or other coumarin derivatives. Source: FDA Ozempic PI 2025 §12.3.
Alcohol (ethanol)
Monitor
Additive GI adverse effects; potential additive hypoglycemia when combined with insulin or sulfonylureas; pancreatitis risk factor. FDA Ozempic label §5.3 (pancreatitis precaution). Advise moderation. Source: FDA Ozempic PI 2025.
Atorvastatin and other statins
Monitor
Atorvastatin DDI study — no clinically relevant PK change. FDA Ozempic label §12.3 and §7.2. No dose adjustment required. Source: FDA Ozempic PI 2025 §12.3.
Digoxin
Monitor
Single-dose DDI study — no clinically relevant change in digoxin exposure. FDA Ozempic label §12.3 and §7.2. No dose adjustment but monitor digoxin levels in setting of severe GI adverse events. Source: FDA Ozempic PI 2025 §12.3.
Metformin
Monitor
No clinically relevant PK interaction at steady state. FDA Ozempic label §12.3 and §7.2. No dose adjustment required. Source: FDA Ozempic PI 2025 §12.3.
Oral hormonal contraceptives (ethinyl estradiol / levonorgestrel) — subcutaneous semaglutide
Monitor
DDI study with ethinyl estradiol/levonorgestrel showed no clinically relevant change in PK at steady state with subQ semaglutide. Delayed gastric emptying is greatest after first dose and after escalation. FDA Ozempic label §12.3 and §7.2. No dose adjustment for subcutaneous semaglutide, but counsel on first-dose absorption uncertainty. Source: FDA Ozempic PI 2025 §12.3.
Retatrutide (Investigational — RUO) 5 interactions
General anesthesia / deep sedation (preoperative aspiration risk)
Major
Class effect — delayed gastric emptying with potential for residual gastric contents during anesthesia. ASA 2023 consensus and 2024 multisociety guidance (PMID: 39550027) apply to all GLP-1RAs including investigational agents. Consider holding once-weekly retatrutide 7 days before elective procedures requiring general anesthesia/deep sedation in research-use settings.
Insulin
Major
Additive hypoglycemia — retatrutide is a GLP-1/GIP/glucagon triple agonist with potent glucose-lowering action via the GLP-1 and GIP arms. The glucagon arm modulates hepatic glucose output and energy expenditure but does not eliminate hypoglycemia risk when exogenous insulin is co-administered. Phase 2 T2D trial protocols required insulin dose reduction at retatrutide initiation. NCT05929079. PMID: 37356068 (Rosenstock et al., Lancet 2023). Class precaution carried over from GLP-1RA labeling.
Other GLP-1 receptor agonists or incretin agonists
Major
Duplicate therapy — no additional efficacy, additive GI and aspiration risks. Investigational status — no clinical data support combination use. Class precaution. PMID: 37356067.
Sulfonylureas (glipizide, glyburide, glimepiride)
Major
Additive hypoglycemia. Class effect — insulin secretagogue plus incretin agonist. Phase 2 T2D trial protocol required sulfonylurea dose reduction. PMID: 37356068. Standard class precaution for GLP-1RA initiation.
Oral hormonal contraceptives
Moderate
Class effect — GLP-1RAs delay gastric emptying and may reduce oral contraceptive absorption. No formal DDI study published for retatrutide as of 2026-06. TRIUMPH protocols included contraceptive guidance for participants of childbearing potential. Class precaution from tirzepatide / Mounjaro labeling extrapolated. PMID: 37356067 (Jastreboff et al., NEJM 2023).
GHK-Cu 1 interaction
Copper-chelating drugs (penicillamine, trientine, tetrathiomolybdate; used in Wilson disease)
Moderate
GHK-Cu delivers a copper(II) ion bound to the glycyl-histidyl-lysyl tripeptide. Patients on copper-chelation therapy for Wilson disease are deliberately maintained in negative copper balance; introducing supplemental copper via GHK-Cu (even topical/SC) is mechanistically contradictory. Concomitant use undermines chelation therapy and risks copper accumulation. Pickart L, Margolina A, 'GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration,' Biomed Res Int 2015 (PMC4508379). Class mechanism from Wilson disease management literature (Roberts EA, Schilsky ML, AASLD Practice Guidelines on Wilson Disease 2008/2022).
Thymosin Alpha-1 3 interactions
Immunosuppressants (cyclosporine, tacrolimus, sirolimus, mycophenolate, corticosteroids at immunosuppressive doses)
Major
Thymalfasin is an immune-system enhancer (T-cell maturation, IFN-gamma upregulation). Use in patients receiving deliberate immunosuppression (organ-transplant maintenance therapy, autoimmune-disease management) is contraindicated unless benefits clearly outweigh risk of graft rejection or autoimmune flare. The Zadaxin product monograph and several national assessments list this as a contraindication / strong caution. Zadaxin (thymalfasin) product monograph, SciClone Pharmaceuticals; RxList Zadaxin Drug Interactions; BPOM (Indonesia FDA equivalent) Thymalfasin assessment report, registrasiobat.pom.go.id, 'Page 1 of 4 THYMOSIN ALFA 1, INJECTION (THYMALFASIN).'
Biologic immunomodulators (TNF-alpha inhibitors, IL-6 inhibitors, JAK inhibitors, anti-CD20 monoclonals)
Moderate
Class extension of the immunosuppression contraindication. Patients on biologics for autoimmune disease (rheumatoid arthritis, IBD, psoriasis, etc.) may experience reduced biologic efficacy or unpredictable immune activation when adding thymalfasin. No published DDI trials; coded `moderate` rather than `major` because clinical events have not been formally documented. Class mechanism per Zadaxin monograph; extrapolation supported by thymalfasin's documented Th1-shift / IFN-gamma effects (Wu Y et al., PMC5406071).
Interferon alfa (peginterferon alfa-2a, peginterferon alfa-2b)
Minor
Thymalfasin is most commonly co-administered with interferon alfa as combination therapy for chronic hepatitis B and C; the combination is the basis of the Zadaxin label indications in many countries. This is a synergistic, intentional combination - not an adverse interaction. Listed here so clinicians recognize it as additive immunostimulation rather than a hazard. Zadaxin product monograph - approved combination indication. Iino S et al., long-standing Asian-region trials of thymalfasin + IFN-alpha for HBV. Listed as `minor` to flag the synergy, not the hazard.
CJC-1295 (with DAC) 4 interactions
Somatostatin analogs (octreotide, lanreotide, pasireotide)
Major
Somatostatin analogs directly antagonize GHRH signaling at the pituitary somatotroph, abolishing the GH-releasing effect of CJC-1295. With a 5.8-8.1 day half-life depot, this pharmacodynamic blockade can persist for weeks. Direct physiologic antagonism. CJC-1295 half-life: Teichman 2006 PMID 16352683. Somatostatin-GHRH antagonism established in classical endocrinology (Brazeau et al, Science 1973; Springer chapter doi:10.1007/978-1-4615-7886-4_18).
Glucocorticoids (prednisone, dexamethasone, hydrocortisone, fludrocortisone)
Moderate
Pharmacologic glucocorticoid doses increase hypothalamic somatostatinergic tone, blunting the GH response to GHRH analogs and reducing CJC-1295 efficacy. Long-acting depot of CJC-1295 makes the interaction sustained. Glucocorticoid suppression of GHRH-driven GH response: Mazziotti & Giustina, Nat Rev Endocrinol 2013;9(5):265-276 (PMID 23438833); also Giustina A et al, J Clin Endocrinol Metab 1995 (PMID 7561633) — GHRH vs hexarelin GH response in glucocorticoid excess.
Insulin and insulin analogs
Moderate
Sustained 1.5-3 fold IGF-1 elevation lasting 9-11 days per dose (Teichman 2006) produces insulin-like glucose disposal effects; concurrent insulin can produce additive hypoglycemia, while chronic GH elevation drives counter-regulatory insulin resistance. Bifaceted glucose effect documented in Teichman SL et al, J Clin Endocrinol Metab 2006;91(3):799-805 (PMID 16352683). Class effect for IGF-1 elevation also documented in Increlex (mecasermin) FDA label, NDA 021839 — Warnings 5.1 Hypoglycemia.
Oral hypoglycemics (sulfonylureas, meglitinides, metformin)
Moderate
Chronic GH/IGF-1 elevation impairs insulin sensitivity (diabetogenic effect of GH) potentially requiring upward dose titration of oral hypoglycemic agents; conversely the IGF-1 spike phase may produce additive hypoglycemia with sulfonylureas/meglitinides. Diabetogenic class effect: Mazziotti G, Giustina A. Glucocorticoids and the regulation of growth hormone secretion. Nat Rev Endocrinol 2013;9(5):265-276 (PMID 23438833) — establishes the GH-glucose axis relevant here. CJC-1295 IGF-1 kinetics: Teichman 2006 PMID 16352683.
CJC-1295 (no DAC) / MOD-GRF 1-29 3 interactions
Somatostatin analogs (octreotide, lanreotide, pasireotide)
Major
Direct physiologic antagonism at the somatotroph — somatostatin analogs abolish the GH response to GHRH(1-29) administration. Classical GHRH-somatostatin antagonism (Brazeau et al, Science 1973); reviewed in Springer chapter doi:10.1007/978-1-4615-7886-4_18.
Glucocorticoids (prednisone, dexamethasone, hydrocortisone)
Moderate
Pharmacologic glucocorticoid doses increase somatostatinergic tone and blunt the acute GH response to short-acting GHRH(1-29) analogs. Effect is per-injection rather than sustained (vs DAC variant). Mazziotti G, Giustina A. Glucocorticoids and the regulation of growth hormone secretion. Nat Rev Endocrinol 2013;9(5):265-276 (PMID 23438833); Giustina A et al, J Clin Endocrinol Metab 1995 (PMID 7561633).
Insulin and oral hypoglycemics
Moderate
Pulsatile GH/IGF-1 elevation from frequent MOD-GRF dosing has class-effect diabetogenic potential (reduced insulin sensitivity, raised fasting glucose) at chronic high-frequency exposure. Less sustained than DAC but cumulative with daily multi-dose protocols. Class effect, extrapolated from MK-677 long-term data (Nass R et al, Ann Intern Med 2008;149:601-611, PMID 18981485) and GH-glucose axis review (Mazziotti & Giustina, PMID 23438833). Direct CJC-1295 no-DAC glucose tolerance trial data is limited.
Ipamorelin 3 interactions
Somatostatin analogs (octreotide, lanreotide, pasireotide)
Major
Somatostatin tonic inhibition of GH release downstream of the ghrelin receptor abolishes ipamorelin's GH-releasing effect. Ipamorelin GH release mechanism: Raun K et al, Eur J Endocrinol 1998;139:552-561 (PMID 9849822). Somatostatin antagonism reviewed in Brazeau Science 1973 and Springer doi:10.1007/978-1-4615-7886-4_18.
Glucocorticoids (prednisone, dexamethasone)
Moderate
Pharmacologic glucocorticoid doses increase somatostatinergic tone and blunt the GH response to ghrelin-receptor agonists. Less pronounced than the GHRH-analog interaction but documented at the pituitary level. Mazziotti G, Giustina A. Nat Rev Endocrinol 2013;9(5):265-276 (PMID 23438833). Class effect for GH secretagogues.
Insulin and oral hypoglycemics
Moderate
Pulsatile GH/IGF-1 elevation produces dose-dependent reductions in insulin sensitivity at sustained exposure. Less severe than non-selective GHRPs that also stimulate cortisol, because ipamorelin's selectivity spares the ACTH/cortisol axis (Raun 1998). Ipamorelin selectivity: Raun K et al, Eur J Endocrinol 1998;139:552-561 (PMID 9849822). GH-glucose axis class effect: Mazziotti & Giustina, PMID 23438833; Nass R et al, Ann Intern Med 2008;149:601-611 (PMID 18981485).
Tesamorelin (Egrifta) 9 interactions
Recombinant human GH / somatropin
Major
Pharmacodynamic duplication — tesamorelin stimulates endogenous GH release, so concurrent exogenous somatropin produces compounded GH/IGF-1 exposure with risk of fluid retention, carpal tunnel, arthralgia, glucose intolerance, and theoretically accelerated proliferative effects. Class-effect contraindication implied by Egrifta WR Section 5.1 (active malignancy contraindication driven by GH/IGF-1 proliferative concern) plus pharmacology. No co-administration study has been conducted.
Glucocorticoid replacement (hydrocortisone, prednisone)
Moderate
Tesamorelin-stimulated endogenous GH inhibits 11β-hydroxysteroid dehydrogenase type 1, decreasing conversion of inactive cortisone to active cortisol. Patients on glucocorticoid replacement for hypoadrenalism may become functionally under-replaced. Egrifta SV FDA label Section 7.1: 'Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV.'
Insulin / sulfonylureas / metformin (any antidiabetic)
Moderate
GH is counter-regulatory to insulin; tesamorelin-driven GH elevation may worsen insulin resistance, increase HbA1c, and precipitate or unmask type 2 diabetes. Antidiabetic regimens may require uptitration. Egrifta SV/WR FDA label Section 5.4 (Warnings): 'Glucose intolerance or diabetes mellitus may develop with EGRIFTA WR use, and glucose should be evaluated prior to and during therapy.' Pivotal phase 3 trials showed small but statistically significant HbA1c rises (PMID: 22106298).
Anticonvulsants (phenytoin, carbamazepine, valproate)
Monitor
GH may alter CYP450 clearance of narrow-therapeutic-index anticonvulsants; therapeutic drug monitoring is appropriate. Egrifta SV FDA label Section 7.2 names anticonvulsants in the CYP450 class.
CYP3A4 substrates (simvastatin, atorvastatin, ethinyl estradiol, midazolam)
Monitor
GH may modulate CYP450-mediated antipyrine clearance. Direct simvastatin coadministration study showed clinically insignificant changes (AUC decreased 8%, Cmax increased 5%), but monitoring is labeled. Egrifta SV FDA label Section 7.2 + Section 12.3: 'Patients should be monitored for potential interactions when administering EGRIFTA SV with cytochrome P450-metabolized drugs.' Simvastatin AUCinf decreased 8%; simvastatin acid AUCinf decreased 15%.
Corticosteroids (oral / inhaled prednisone, dexamethasone)
Monitor
GH-mediated CYP450 modulation may alter clearance of corticosteroids beyond glucocorticoid replacement contexts (e.g., chronic inflammatory dosing). Egrifta SV FDA label Section 7.2 lists corticosteroids as a CYP450 class of concern.
Cyclosporine and other immunosuppressants
Monitor
GH alteration of CYP3A4 clearance may shift cyclosporine trough levels. Egrifta SV FDA label Section 7.2 cites cyclosporine explicitly.
Levothyroxine / thyroid hormone replacement
Monitor
GH increases conversion of T4 to T3 and may increase clearance of T4. Hypothyroid patients on stable replacement may need TSH monitoring and dose increase after starting tesamorelin. Class effect of GH replacement broadly documented (PMID: 12915664, Jorgensen et al. 1994). Egrifta WR Section 5.5: 'Patients receiving thyroid hormone replacement may require an increase in their thyroid hormone replacement dose.'
Sex steroids (oral contraceptives, testosterone, estradiol)
Monitor
GH may alter clearance of CYP450-metabolized sex steroids. Egrifta SV FDA label Section 7.2 names sex steroids in the CYP450 monitoring class.
Sermorelin 5 interactions
Somatostatin analogs (octreotide, lanreotide, pasireotide)
Major
Direct physiologic antagonism — somatostatin analogs block GH release at the somatotroph, abolishing sermorelin's effect. Geref label warns against concurrent use. Mechanism reviewed in Springer doi:10.1007/978-1-4615-7886-4_18.
Antithyroid agents (propylthiouracil, methimazole)
Moderate
Per historic Geref label: antithyroid agents can suppress the GH response to sermorelin, complicating diagnostic interpretation and reducing therapeutic GH release. Geref (sermorelin acetate) FDA prescribing information, NDA 020443 — Drug Interactions section. Preserved in RxList monograph.
Glucocorticoids (prednisone, dexamethasone, hydrocortisone — chronic pharmacologic doses)
Moderate
Per historic Geref label: chronic glucocorticoid therapy inhibits the GH response to sermorelin via increased hypothalamic somatostatinergic tone, reducing both diagnostic and therapeutic efficacy. Geref (sermorelin acetate) FDA prescribing information, NDA 020443 (Serono) — Drug Interactions section; preserved in RxList monograph (https://www.rxlist.com/sermorelin-acetate-drug.htm). Mechanism: Mazziotti & Giustina, Nat Rev Endocrinol 2013;9(5):265-276 (PMID 23438833).
Thyroid hormone (levothyroxine — supraphysiologic doses)
Moderate
Per historic Geref label: thyroid hormone in excess of replacement requirements may attenuate the GH response to sermorelin and other GHRH analogs. Geref (sermorelin acetate) FDA prescribing information, NDA 020443 — Drug Interactions section; preserved in RxList monograph. Drugs.com sermorelin+levothyroxine interactions entry (https://www.drugs.com/drug-interactions/sermorelin-with-synthroid-2055-0-1463-869.html).
Muscarinic antagonists (atropine, scopolamine, anticholinergic agents)
Minor
Per historic Geref label: muscarinic cholinergic antagonists may blunt the GH response to GHRH analogs via central cholinergic-somatostatin pathway interaction. Geref (sermorelin acetate) FDA prescribing information, NDA 020443 — Drug Interactions; RxList monograph. Class effect for GHRH-based provocative testing.
MK-677 / Ibutamoren (oral) 6 interactions
Somatostatin analogs (octreotide, lanreotide, pasireotide)
Major
Somatostatin analogs antagonize GH release downstream of the ghrelin receptor, abolishing MK-677's GH-elevating effect. Class effect for ghrelin-receptor agonists. Mechanism reviewed in Springer doi:10.1007/978-1-4615-7886-4_18.
Glucocorticoids (prednisone, dexamethasone — chronic pharmacologic)
Moderate
Pharmacologic glucocorticoids blunt the GH response to ghrelin-receptor agonists via increased somatostatinergic tone, reducing MK-677 efficacy. Class effect for GH secretagogues. Mazziotti & Giustina, Nat Rev Endocrinol 2013;9(5):265-276 (PMID 23438833). Chapman IM et al, J Clin Endocrinol Metab 1996;81(12):4249-4257 (PMID 8954023) establishes the axis.
Insulin and insulin analogs
Moderate
Chronic GH/IGF-1 elevation from daily oral MK-677 reduces insulin sensitivity (Nass 2008 documented +5 mg/dL fasting glucose and HbA1c rise sustained over 2 years), potentially requiring upward insulin dose adjustment. Insulin requirements may shift over time as the diabetogenic effect of GH develops. Nass R et al, Ann Intern Med 2008;149(9):601-611 (PMID 18981485). Mechanism review: Mazziotti & Giustina, Nat Rev Endocrinol 2013;9(5):265-276 (PMID 23438833).
Oral hypoglycemics (metformin, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors)
Moderate
MK-677-induced insulin resistance counter-regulates oral hypoglycemic efficacy. Particularly relevant for prediabetes / T2DM patients; HbA1c rise of approximately 0.3% over baseline documented in healthy elderly without diabetes (Nass 2008). Nass R et al, Ann Intern Med 2008;149(9):601-611 (PMID 18981485).
QT-prolonging drugs (amiodarone, sotalol, dofetilide, citalopram, ondansetron, methadone)
Moderate
MK-677 has shown modest QTc prolongation in pharmacologic studies; concurrent use with other QT-prolonging agents requires monitoring. The signal was strong enough to be a factor in MK-677's failed Alzheimer's trial endpoint analyses. MK-677 cardiac repolarization signal documented in Phase 2 trial datasets — see NCATS Inxight entry (https://drugs.ncats.io/drug/GJ0EGN38UL) and Sevigny J et al, Neurology 2008;71(21):1702-1708 (PMID 18814242) — MK-677 in mild-to-moderate Alzheimer's safety summary.
Fluid-retaining drugs (NSAIDs, calcium channel blockers, thiazolidinediones)
Minor
MK-677 promotes GH/IGF-1-mediated sodium and water retention; concurrent use with other fluid-retaining agents can produce additive edema, particularly in older adults. Edema was the most common adverse event in Nass 2008. Nass R et al, Ann Intern Med 2008;149(9):601-611 (PMID 18981485) — edema reported in approximately one-third of MK-677 subjects. Mechanism: standard GH-mediated fluid retention.
MOTs-c 1 interaction
Metformin (and other mitochondrial-acting biguanides)
Monitor
MOTS-c and metformin both act on mitochondrial metabolism and AMPK signaling; metformin treatment alters circulating MOTS-c levels in patients. There are no published reports of clinically harmful additive effects, but the shared mechanism (AMPK activation, improved insulin sensitivity) creates theoretical risk of additive hypoglycemia in patients taking metformin plus insulin or sulfonylureas. Monitor glycemic control. Cataldo LR et al., 'Circulating levels of MOTS-c in patients with breast cancer treated with metformin,' (PMC10008497). Wei M et al., 'MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation,' Front Endocrinol 2023;14:1120533.
NAD+ 6 interactions
Active chemotherapy (pyrimidine analogues, alkylators, anthracyclines)
Major
NAD+ is a substrate for PARP1, SIRT1/3, and CD38; supraphysiologic NAD+ supports DNA-damage repair and mitochondrial respiration in cancer cells, potentially reducing chemotherapy-induced apoptosis. Vitamin B3 derivatives have been shown to support pancreatic cancer cell survival and chemoresistance. Avoid NAD+ infusions during active cytotoxic chemotherapy unless coordinated with oncology. AACR Cancer Research 2025 Abstract A128; PMC7175378 (Nikas et al., Cancers 2020 review of nicotinamide in cancer chemoprevention/therapy).
Antihypertensives / vasodilators
Moderate
NAD+ infusions transiently lower systolic BP via prostaglandin-mediated vasodilation; additive hypotension with ACE inhibitors, ARBs, alpha-blockers, or nitrates. Infusion protocols require holding when SBP <100 mmHg. Hubmed clinical safety summary 2026; PeachIV NAD+ safety profile; Frontiers in Aging 2026 (PMC12907335).
CD38-inhibiting / immunomodulatory agents (e.g., daratumumab, isatuximab)
Moderate
CD38 is the dominant NAD+ ectoenzyme. CD38-targeting monoclonal antibodies alter systemic NAD+ catabolism; coadministration with supraphysiologic NAD+ confounds both the antibody's pharmacodynamic readout and NAD+ steady-state levels. Mechanistic interaction — Chini et al., PMC reviews on CD38 and NAD+ metabolism. No clinical DDI study published; coordinate with hematology/oncology.
Monoamine oxidase inhibitors (MAOIs)
Moderate
Theoretical interaction via altered methylation flux and catecholamine turnover; NAD+ infusion clinics universally list MAOIs as a relative contraindication due to hemodynamic unpredictability during the infusion. Listed as contraindication in clinician summaries (DrOracle 2026 NAD+ IV contraindications review).
Niacin / nicotinic acid (lipid therapy)
Moderate
Additive flushing, pruritus, and prostaglandin-mediated vasodilation. Both compounds feed the NAD+ salvage and de novo pathways, and combined supraphysiologic dosing amplifies cutaneous vasomotor effects. Common practical interaction reported in retrospective IV-NAD+ tolerability cohorts. Frontiers in Aging 2026 (PMC12907335) — Brunoni et al., NAD+ vs NR IV tolerability pilot.
Metformin / biguanides
Monitor
Both modulate NAD+/NADH redox ratio. Metformin lowers hepatic NAD+ indirectly via complex I inhibition; exogenous NAD+ may blunt metformin's AMPK-mediated effect or, conversely, restore mitochondrial substrate balance. Net clinical effect on glycemic control is undefined. Mechanistic plausibility from JCI 13505 (Zhou et al., metformin/AMPK) and PMC4582151 (AICAR vs metformin in beta cells). No human DDI trial exists; monitor glucose during initiation.
5-Amino-1MQ 2 interactions
Antidiabetic agents (metformin, GLP-1 agonists, insulin)
Monitor
5-Amino-1MQ reversed obesity and improved glucose tolerance in DIO mice; additive glycemic effects with insulin or insulin secretagogues are mechanistically plausible. Human pharmacokinetic and PD data are absent. Preclinical — Neelakantan et al. mouse DIO data; no human studies. Monitor glucose in users on antidiabetics.
SAM-methyl-cycle substrates (high-dose niacin, nicotinamide, betaine, methylfolate, methylcobalamin)
Monitor
NNMT consumes SAM and nicotinamide; inhibiting NNMT raises intracellular SAM and nicotinamide. Coadministration with high-dose methyl donors or nicotinamide could amplify the methylation-cycle shift in unpredictable directions in preclinical models. Mechanistic only — derived from the published NNMT/SAM pathway model (Neelakantan et al., Biochem Pharmacol 2017; Kannt et al., Sci Rep 2018). No human DDI study exists. Monitor when co-supplementing methyl donors.
Selank 2 interactions
Benzodiazepines (diazepam, phenazepam, medazepam)
Monitor
Selank acts on GABA-A at a site distinct from the benzodiazepine binding site and modulates expression of GABA-A subunit genes. In animal and small Russian clinical studies, co-administration with diazepam or phenazepam potentiated anxiolysis and reduced typical benzodiazepine side-effects (sedation, attention deficit). The interaction is pharmacodynamic at the GABAergic system; net effect is enhanced anxiolysis rather than toxicity, but additive CNS depression cannot be excluded at higher doses. Kolomin T et al., 'Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission,' Front Pharmacol 2016;7:31 (PMC4757669). Kasian A et al., 'Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats,' Biomed Res Int 2017 (PMC5322660). Russian clinical anxiolytic combination data also referenced in product monograph.
CNS depressants (alcohol, opioids, sedating antihistamines)
Monitor
Theoretical additive central GABAergic / sedative effect given Selank's positive allosteric modulation of GABA-A signaling. No formal DDI trials; caution flag rather than established interaction. Mechanistic inference from GABA-A modulation documented in PMC4757669. No human DDI data published in indexed literature.
Semax 3 interactions
Psychostimulants (amphetamine, methylphenidate, modafinil)
Moderate
Semax potentiates extracellular dopamine elevations and locomotor responses produced by D-amphetamine in rodent striatum. Mechanism is augmentation of dopaminergic and serotonergic tone via Semax's ACTH(4-7) backbone. Clinically, this implies additive dopaminergic stimulation when combined with prescription stimulants - increased risk of insomnia, tachycardia, anxiety, and potentially elevated blood pressure. Eremin KO et al., 'Semax potentiates effects of D-amphetamine on the level of extracellular dopamine in the Sprague-Dawley rat striatum and on the locomotor activity of C57BL/6 mice,' Eksp Klin Farmakol 2004;67(1):8-10 (PMID 15188751). Eremin KO et al., 'Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents,' Neurochem Res 2005;30(12):1493-500 (PMID 16362768).
MAOIs (phenelzine, tranylcypromine, selegiline, moclobemide)
Monitor
Theoretical risk of additive monoaminergic effects given Semax's documented activation of dopaminergic and serotonergic systems. No human DDI study has been conducted; the flag is mechanistic / class-effect rather than evidence-based. Mechanistic inference from Eremin 2005 (PMID 16362768) demonstrating dopaminergic / serotonergic activation. No clinical reports of serotonin syndrome with Semax in indexed literature.
SSRIs / SNRIs
Monitor
Theoretical risk based on documented serotonergic activation by Semax in rodent brain. Risk magnitude unknown; no clinical case reports of serotonin syndrome attributable to Semax + SSRI combination exist in indexed literature. Mechanistic inference from Eremin 2005 (PMID 16362768). Caution flag only - no human DDI data.
DSIP 1 interaction
CNS depressants and sleep-promoting agents (benzodiazepines, Z-drugs, sedating antihistamines, alcohol, melatonin)
Monitor
DSIP's molecular target receptor remains unidentified despite 40+ years of research; classical receptor-binding studies are inconclusive. Theoretical additive sedation when combined with established sleep-promoting agents, but no human DDI study has been published. PubMed 6145137 (Graf & Kastin, Peptides 1984 review); European Journal of Anaesthesiology 2001 editorial (Cambridge core S0265021501000898a). Monitor flag reflects the receptor uncertainty, not a documented interaction.
PT-141 / Bremelanotide 6 interactions
Antihypertensives / patients with uncontrolled hypertension or known cardiovascular disease
Major
Vyleesi transiently increases blood pressure (mean +6 mmHg SBP / +3 mmHg DBP, peak 2-4 hr post-dose) and reduces heart rate (up to -5 bpm). Use is CONTRAINDICATED in uncontrolled hypertension or known cardiovascular disease. Not recommended in patients at high cardiovascular risk. Antihypertensive regimens should be optimized and BP should be well-controlled before initiation. Vyleesi FDA PI §4 (Contraindications) and §5.1 (Warnings and Precautions: Transient Increase in Blood Pressure); §12.2 (Pharmacodynamics, ABPM study n=127). Reference ID 4452852.
Oral naltrexone (alcohol/opioid use disorder products)
Major
Vyleesi significantly decreases systemic exposure of orally-administered naltrexone (via slowed gastric emptying / reduced absorption). The FDA label specifically directs avoidance because naltrexone treatment failure has 'severe consequences' (loss of opioid-blockade or alcohol-craving control). Applies to oral naltrexone-containing products intended to treat alcohol or opioid addiction. Vyleesi (bremelanotide) FDA Prescribing Information §7.2 and §12.3; AMAG Pharmaceuticals, NDA 210557, June 2019; Reference ID 4452852.
Oral antibiotics requiring threshold plasma concentrations
Moderate
Because Vyleesi slows gastric emptying and may reduce the rate/extent of oral drug absorption, the FDA label explicitly instructs patients to avoid Vyleesi use when taking concomitant oral drugs that depend on threshold concentrations for efficacy, citing antibiotics as the example. Vyleesi FDA PI §7.1; Reference ID 4452852.
Oral indomethacin (and other NSAIDs/analgesics where time-to-onset matters)
Moderate
Vyleesi slows gastric emptying and reduces the rate and extent of absorption of concomitant oral medications. Indomethacin is the second oral drug (after naltrexone) explicitly identified in the FDA label as having clinically relevant exposure changes. Patients should consider discontinuing Vyleesi if a delayed drug effect of oral pain-relief medication is unacceptable. Vyleesi FDA PI §7.1 (Effect of VYLEESI on Other Drugs) and §12.3 (Drug Interaction Studies); Reference ID 4452852.
Oral medications requiring rapid onset (e.g., acute pain relievers)
Moderate
Vyleesi-induced gastric emptying slowdown delays the onset of action of orally administered drugs taken near the time of Vyleesi dose. The FDA label specifies this concern for pain-relief drugs where a quick onset is desired. Vyleesi FDA PI §7.1; Reference ID 4452852.
Alcohol (ethanol)
Minor
A placebo-controlled crossover study (n=24, intranasal 20 mg bremelanotide + 0.6 g/kg ethanol) found no effect of alcohol on bremelanotide pharmacokinetics. Flushing and headache incidences were slightly altered but no clinically significant interaction or orthostatic effect was observed. The label does not restrict alcohol but documents the interaction study for completeness. Vyleesi FDA PI §12.2 (Pharmacodynamics, Alcohol Interaction); Reference ID 4452852.
Melanotan II 2 interactions
Sympathomimetics, vasopressors, stimulants (amphetamines, cocaine, decongestants)
Major
Documented case of systemic sympathomimetic-like toxicity (tachycardia 130-146 bpm, hypertension 151/85, mydriasis, diaphoresis, muscle tremors, rhabdomyolysis with CPK >2622, acute kidney injury) following a single 6 mg SC dose. Additive vasopressor and tachycardic effects with concomitant sympathomimetics raise risk of hypertensive crisis and rhabdomyolysis. Nelson LS, Bryant SM, 'Melanotan II injection resulting in systemic toxicity and rhabdomyolysis,' Clin Toxicol (Phila) 2012;50(10):1169-73 (PMID 23121206; DOI 10.3109/15563650.2012.740637).
Antihypertensives (similar to bremelanotide class effect)
Moderate
Melanotan-2 is a non-selective melanocortin agonist sharing MC4R activity with bremelanotide. The class effect of transient blood pressure elevation is documented for the FDA-approved sibling (Vyleesi, max +6/+3 mmHg) and is plausibly applicable to Melanotan-2. Patients on antihypertensives should be monitored. Class extrapolation from Vyleesi FDA PI §5.1 (Reference ID 4452852); confirmed BP elevation in the Nelson 2012 case report (PMID 23121206).
Glutathione 5 interactions
Platinum-based chemotherapy (cisplatin, carboplatin, oxaliplatin)
Major
Glutathione directly conjugates platinum drugs via its cysteine thiol, deactivating them and accelerating renal clearance. Elevated intracellular glutathione is one of the principal mechanisms of cisplatin resistance in tumor cells. Exogenous glutathione may reduce antitumor efficacy of platinum chemotherapy. Some controlled trials used IV glutathione as a NEUROPROTECTANT during cisplatin chemo without loss of antitumor effect, but co-administration outside an oncology protocol is contraindicated. Smyth JF et al., 'Influence of glutathione administration on the disposition of free and total platinum in patients after administration of cisplatin,' Ann Oncol 1992 (PMID 1312907). Chen HHW, Kuo MT, 'Role of Glutathione in the Regulation of Cisplatin Resistance in Cancer Chemotherapy,' Met Based Drugs 2010 (PMC2946579). Smyth JF et al., 'Dose intensification of platinum compounds with glutathione protection as induction chemotherapy for advanced ovarian carcinoma,' Ann Oncol 1999 (PMID 10461057).
Acetaminophen (paracetamol)
Moderate
Acetaminophen overdose depletes hepatic glutathione, allowing the toxic NAPQI metabolite to bind hepatocyte proteins. Exogenous glutathione (or its precursor N-acetylcysteine) replenishes the conjugation substrate and is hepatoprotective. This is a BENEFICIAL pharmacodynamic interaction in overdose; in therapeutic acetaminophen use the interaction is not clinically significant. Coded `moderate` because clinicians should know glutathione affects acetaminophen detoxification kinetics. Tee LB et al., 'Toxicity of paracetamol in human hepatocytes. Comparison of the protective effects of sulfhydryl compounds acting as glutathione precursors,' Biochem Pharmacol 1986 (PMID 3509688). James LP et al., 'Hepatic glutathione depletion and susceptibility to hepatotoxicity after paracetamol overdose,' (PMC4753970).
Doxorubicin and other reactive-oxygen-species-dependent chemotherapy (anthracyclines, bleomycin, alkylating agents)
Moderate
Anthracyclines and bleomycin produce cytotoxicity in part via ROS generation. Glutathione is the principal cellular antioxidant; exogenous GSH or NAC may theoretically reduce the antitumor effect of ROS-dependent agents. Clinical magnitude is debated; oncologists generally avoid high-dose antioxidants during chemotherapy. Chen HHW, Kuo MT, 2010 (PMC2946579) discusses GST/GSH-mediated chemoresistance broadly. Extrapolation to anthracyclines is mechanistic; clinical evidence is mixed but caution is the standard oncologic position.
N-acetylcysteine (NAC)
Minor
NAC is the cysteine precursor that drives endogenous glutathione synthesis. Co-administration with exogenous glutathione is pharmacodynamically additive (both raise intracellular GSH). No toxicity expected; the interaction is duplicative therapy rather than dangerous. Relevant when both are used for acetaminophen toxicity or oxidative-stress indications. Whillier S et al., reviewed in Mechanism of N-acetylcysteine in acetaminophen protection (PMC436956); ScienceDirect 'N-acetylcysteine: 50 years since the discovery of an antidote' review.
Nitroglycerin and organic nitrates
Monitor
Nitrate tolerance is partly mediated by intracellular thiol (glutathione) depletion. Replenishing thiols with N-acetylcysteine has been shown to restore nitrate responsiveness; exogenous glutathione is theoretically similar. Co-administration could enhance nitrate effects (increased hypotension). Limited clinical data. Class mechanism: Munzel T et al., reviews of nitrate tolerance and thiol depletion (multiple PubMed citations, e.g., PMID 8597127). Glutathione-specific human DDI data is sparse; coded `monitor`.
HCG 6 interactions
Androgens / exogenous testosterone (testosterone cypionate, enanthate)
Moderate
Both stimulate androgenic effects (hCG via Leydig-cell stimulation, exogenous T directly). Concurrent use compounds fluid retention, polycythemia, and androgenic side effects. Exogenous T suppresses endogenous LH and may blunt hCG-driven testicular response over time. Pregnyl FDA label Precautions: 'Since androgens may cause fluid retention, HCG should be used with caution in patients with cardiac or renal disease, epilepsy, migraine, or asthma.' Class-effect concern; relevant to TRT-adjunct off-label use.
Anticoagulants (warfarin, DOACs — apixaban, rivaroxaban)
Moderate
hCG-driven ovarian stimulation increases estradiol and shifts hemostatic balance toward thrombosis (OHSS-associated thromboembolism is a documented serious adverse reaction). Anticoagulants may need monitoring; estrogenic rise may also accelerate warfarin clearance. Pregnyl FDA label Warnings names 'arterial thromboembolism' among principal serious adverse reactions. PMID 18460386 (Chan et al., thromboembolism with assisted reproduction).
Aromatase inhibitors (anastrozole, letrozole) and SERMs (clomiphene, tamoxifen)
Moderate
Co-administered intentionally in many fertility / TRT-adjunct protocols. Interaction is not adverse but pharmacodynamically intentional — letrozole/clomiphene drives endogenous FSH; hCG triggers ovulation or sustains Leydig-cell function. Listed to flag clinical awareness, not avoidance. Standard ART/fertility protocols (PMID 20347429, Casper & Mitwally letrozole protocol). Pregnyl label does not list these as interactions but the combination defines current clinical practice.
Menotropins / FSH preparations (Menopur, Gonal-F, Follistim)
Moderate
Synergistic ovarian/testicular stimulation. hCG mimics LH activity; concurrent FSH stimulation in fertility protocols dramatically increases ovarian hyperstimulation syndrome (OHSS) risk, multifetal pregnancy, and arterial thromboembolism. Pregnyl FDA label Warnings: 'The principal serious adverse reactions include ovarian hyperstimulation (a syndrome of sudden ovarian enlargement, ascites with or without pain, and/or pleural effusion), rupture of ovarian cysts with resultant hemoperitoneum, multiple births, and arterial thromboembolism.' Used clinically in combination but requires close monitoring with estradiol + transvaginal US.
Corticosteroids (prednisone, dexamethasone)
Monitor
Both promote fluid retention; concurrent use compounds edema risk. Corticosteroids are also routinely co-prescribed in some fertility protocols and during OHSS management — interaction is bidirectional context-dependent. Pregnyl Precautions: hCG androgenic fluid-retention warning. Class effect — not a contraindication.
Loop / thiazide diuretics (furosemide, hydrochlorothiazide)
Monitor
hCG/androgen fluid retention may oppose diuretic effect; in OHSS management diuretics may be used cautiously due to intravascular volume depletion risk. Electrolyte monitoring (K+, Mg2+) prudent. Pregnyl Precautions (cardiac/renal caution language). PMID 12372778 (Whelan & Vlahos, OHSS management review).
Gonadorelin 4 interactions
Dopamine antagonists / phenothiazines (haloperidol, risperidone, metoclopramide, prochlorperazine)
Moderate
These agents raise prolactin by blocking pituitary D2 receptors. Hyperprolactinemia downregulates pituitary GnRH receptors, blunting gonadorelin-induced LH/FSH response. Both diagnostic (Factrel test) and therapeutic (TRT-adjunct pulsatile) responses are reduced. Factrel FDA label Drug Interactions: 'The response to Factrel may be blunted by phenothiazines and dopamine antagonists which cause a rise in prolactin.'
Glucocorticoids (prednisone, dexamethasone) at HPA-suppressive doses
Moderate
Chronic glucocorticoid use suppresses hypothalamic CRH/GnRH co-regulation and may blunt gonadorelin response. Diagnostic interpretation is unreliable; therapeutic pulsatile dosing may be less effective. Factrel FDA label Drug Interactions explicitly lists glucocorticoids.
Sex steroids (androgens, estrogens, progestins, oral contraceptives)
Moderate
Exogenous sex steroids exert negative feedback on the hypothalamic-pituitary axis, suppressing endogenous LH/FSH and altering the pituitary's response to gonadorelin. Confounds diagnostic test results and reduces therapeutic effect of pulsatile gonadorelin. Factrel FDA label Drug Interactions: 'The Factrel test should be conducted in the absence of other drugs which directly affect the pituitary secretion of the gonadotropins. These would include a variety of preparations which contain androgens, estrogens, progestins, or glucocorticoids.'
Spironolactone / antiandrogens (cyproterone, bicalutamide, finasteride)
Monitor
These agents alter the feedback environment of the HPG axis. Antiandrogens may paradoxically increase LH/FSH response to gonadorelin; spironolactone has mineralocorticoid + antiandrogen effects that confound test interpretation. Class effect from gonadorelin pharmacology (PMID 4007746, Yen — gonadotropin response in HPG axis). Not explicit in Factrel label but flagged in endocrinology references.
Cagrilintide 3 interactions
Insulin
Major
Amylin agonists delay gastric emptying and suppress glucagon, contributing to hypoglycemia when combined with exogenous insulin. Pramlintide labeling (the only FDA-approved amylin analogue) requires a 50% insulin dose reduction at amylin initiation. Phase 2 cagrilintide trial protocols required insulin caution. PMID: 34298010 (Enebo et al., Lancet 2021). Class precaution carried over from Symlin (pramlintide) PI. Source: REDEFINE 1 protocol; Symlin PI.
General anesthesia / deep sedation (preoperative aspiration risk)
Moderate
Class effect — amylin analogues delay gastric emptying similarly to GLP-1RAs. No formal label exists for cagrilintide monotherapy. ASA 2023 guidance for GLP-1RAs is reasonable to extrapolate. Multisociety 2024 update (PMID: 39550027) discusses gastric emptying agents broadly. Hold once-weekly cagrilintide 7 days prior to elective procedures requiring general anesthesia / deep sedation.
Other gastric-emptying-delaying agents — GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide, retatrutide), opioids, anticholinergics
Moderate
Additive delayed gastric emptying. Note that CagriSema (cagrilintide + semaglutide fixed-dose combination) is an INTENDED combination with documented safety — this caution applies to OTHER GLP-1RA combinations not covered by CagriSema labeling. REDEFINE 1 and REDEFINE 2 trials established the safety profile of cagrilintide + semaglutide specifically; combining cagrilintide with any other GLP-1RA is not supported by clinical data. PMID: 40522043 (NEJM 2025, REDEFINE 1) and PMID: 40522044 (NEJM 2025, REDEFINE 2). Source: NEJMoa2502081, NEJMoa2502082.
CagriSema 7 interactions
General anesthesia / deep sedation (preoperative aspiration risk)
Major
Both components delay gastric emptying; once-weekly dosing means residual exposure persists for at least 1 week. ASA 2023 + multisociety 2024 (PMID: 39550027) GLP-1RA guidance applies. Hold CagriSema 7 days before elective procedures requiring general anesthesia / deep sedation. Source: Wegovy PI 2025; ASA Consensus.
Insulin
Major
Additive hypoglycemia — both the semaglutide and the cagrilintide components contribute. Effect is more pronounced than with either component alone because amylin agonism suppresses glucagon while GLP-1 agonism augments insulin secretion. REDEFINE 1 protocol required insulin dose reduction at CagriSema initiation. PMID: 40522043. Reduce insulin dose at CagriSema initiation; monitor glucose. Source: NEJMoa2502081; Wegovy PI 2025 §7.1.
Other GLP-1 receptor agonists / incretin agonists or amylin analogues (semaglutide alone, tirzepatide, liraglutide, dulaglutide, exenatide, retatrutide, orforglipron, cagrilintide alone, pramlintide)
Major
Duplicate therapy — CagriSema already contains semaglutide and cagrilintide. Coadministration with any other GLP-1RA, incretin agonist, or amylin analogue is duplicative. Not studied. Avoid. Source: REDEFINE protocols; pharmacologic class principle.
Sulfonylureas (glipizide, glyburide, glimepiride)
Major
Additive hypoglycemia — same mechanism as insulin combination. REDEFINE 2 protocol (T2D population) required sulfonylurea dose reduction. PMID: 40522044. Source: NEJMoa2502082.
Narrow-therapeutic-index oral drugs (digoxin, levothyroxine, phenytoin, lithium, cyclosporine, tacrolimus)
Moderate
Additive delayed gastric emptying may alter rate of absorption. Inherited from semaglutide labeling §7.2 and cagrilintide class effect. Monitor as clinically indicated. Source: Wegovy PI 2025 §7.2; REDEFINE protocol.
Oral hormonal contraceptives
Moderate
Both components delay gastric emptying; semaglutide alone showed no clinically relevant effect on combined oral contraceptive PK but cagrilintide may add additional gastric-emptying delay. REDEFINE trials required reliable contraception for participants of childbearing potential. PMID: 40522043. Counsel patients on barrier method during first 4 weeks of therapy out of caution pending CagriSema label. Source: REDEFINE protocol; Wegovy PI 2025 §7.3.
Warfarin and coumarin anticoagulants
Moderate
Semaglutide component carries an INR-monitoring recommendation from Ozempic label; cagrilintide adds delayed gastric emptying. Monitor INR more frequently at CagriSema initiation. Source: Wegovy/Ozempic PI 2025 §7.2; REDEFINE.
SS-31 4 interactions
MATE1 substrates (metformin, cimetidine, procainamide, dofetilide)
Moderate
Elamipretide is an in vitro inhibitor of renal MATE1 (IC50 3.53 μM). MATE1 mediates renal tubular secretion of cationic drugs. Inhibition may elevate plasma concentrations of MATE1 substrates, particularly metformin in patients with reduced renal function (which itself increases elamipretide and metabolite exposure). FORZINITY FDA label Section 12.3 (Drug Interaction Studies, In Vitro): 'Elamipretide is an inhibitor of MATE1 (IC50 3.53 μM).' No clinical study has quantified the magnitude of in vivo interaction.
Aspirin (antiplatelet)
Minor
Studied clinically — elamipretide IV infusion (0.1 mg/kg/h x 4 h) did NOT affect aspirin or salicylic-acid PK, and did NOT impair aspirin's antiplatelet activity. Listed for completeness — no clinically meaningful interaction. FORZINITY FDA label Section 12.3 (In Vivo Clinical Studies): aspirin coadministration negative for PK or PD interaction.
Clopidogrel (antiplatelet)
Minor
Elamipretide IV (0.1 mg/kg/h x 4 h) did not significantly affect clopidogrel PK or its antithrombotic activity in healthy subjects. FORZINITY FDA label Section 12.3 (In Vivo Clinical Studies): clopidogrel coadministration negative for interaction.
Unfractionated heparin
Minor
Elamipretide IV (0.25 mg/kg/h x 4 h) did not significantly affect aPTT or anti-factor Xa activity of UFH when coadministered 7 h after UFH infusion start. FORZINITY FDA label Section 12.3 (In Vivo Clinical Studies): UFH coadministration negative for interaction.
Adipotide (FTPP) 4 interactions
Aminoglycoside antibiotics (gentamicin, tobramycin, amikacin)
Major
Aminoglycosides accumulate in proximal tubular cells and produce dose-dependent tubular necrosis — the same anatomic site adipotide damages. Additive nephrotoxicity is mechanistically near-certain. Standard nephrotoxicity-additive class; Arrowhead Phase 1 trial precedent.
Iodinated radiocontrast media (IV contrast for CT, angiography)
Major
Contrast-induced nephropathy (proximal tubular injury and medullary hypoxia) overlaps mechanistically with adipotide's tubular toxicity. Coadministration in a renally vulnerable user materially elevates AKI risk. PMC6927993 nephrotoxicity review; Arrowhead Phase 1 safety findings. Avoid contrast studies within the dosing window without renal-function monitoring.
Nephrotoxic NSAIDs (ibuprofen, naproxen, diclofenac, ketorolac)
Major
Adipotide's Phase 1 trial in castrate-resistant prostate cancer at MD Anderson was discontinued because of universal renal toxicity (proximal tubular injury). Adding NSAID-induced reductions in renal prostaglandin synthesis and afferent arteriolar tone compounds the risk of acute tubular necrosis and acute kidney injury. Arrowhead Phase 1 trial discontinuation reports; PMC6927993 (Lucas et al., NSAID nephrotoxicity mechanism review). Mechanistically additive even without a published formal DDI trial.
Other nephrotoxic agents — vancomycin, calcineurin inhibitors (cyclosporine, tacrolimus), amphotericin B, cisplatin, tenofovir disoproxil
Major
All cause proximal tubular and/or interstitial injury. Concurrent use with a compound that produced trial-halting nephrotoxicity at therapeutic doses is contraindicated outside of monitored clinical settings. Standard nephrotoxicity-additive class. Adipotide was discontinued from clinical development for renal safety; the calc-app default dose was removed per audit #529. The safety floor here is 'avoid the compound entirely,' but if a user proceeds, these classes amplify risk substantially.
AICAR 4 interactions
Athletic / competitive-sport context (regulatory, not pharmacologic)
Major
Not a pharmacologic interaction — AICAR is on the WADA Prohibited List (Section S4.5, Hormone & Metabolic Modulators / AMPK activators) at all times, in and out of competition, since January 2009. Use produces an adverse analytical finding and a multi-year competitive ban. WADA Prohibited List 2026; USADA 'AICAR and other AMPK activators' advisory. Listed here so the calculator can warn athletes — regulatory, not biochemical.
Insulin and insulin secretagogues (sulfonylureas, glinides)
Moderate
AICAR/AMPK activation increases skeletal-muscle glucose uptake independently of insulin signaling; additive hypoglycemia risk when combined with insulin or insulin secretagogues. Diabetologia 2008 (Zhang et al., AMPK activators in T2DM, doi 10.1007/s00125-008-1115-8). Monitor glucose closely.
Metformin and other AMPK activators
Moderate
Both activate AMPK — AICAR directly (phosphorylated intracellularly to ZMP, an AMP mimetic), metformin indirectly via complex I inhibition and altered AMP:ATP ratio. Combined exposure produces additive AMPK activation with potential additive lactate elevation and beta-cell apoptosis at high doses. JCI 13505 (Zhou et al. 2001); PMC4582151 (Cai et al. 2015, AICAR + metformin in INS-1E beta cells, differential downstream mechanisms with both pro-apoptotic at high dose).
SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin)
Monitor
SGLT2 inhibitors activate AMPK secondarily via caloric loss and altered substrate availability; coadministration with AICAR could produce additive AMPK signaling and theoretical additive euglycemic ketoacidosis risk. Mechanistic — no human DDI trial. Carry a 'monitor' classification while published evidence is limited.
Oxytocin 8 interactions
Cyclopropane anesthesia (historical inhaled anesthetic)
Major
Cyclopropane potentiates oxytocin's cardiovascular effects — produces unexpected hypotension and maternal sinus bradycardia with abnormal AV rhythms when coadministered. Pitocin FDA label Precautions section: 'Cyclopropane anesthesia may modify oxytocin's cardiovascular effects, so as to produce unexpected results such as hypotension. Maternal sinus bradycardia with abnormal atrioventricular rhythms has also been noted when oxytocin was used concomitantly with cyclopropane anesthesia.'
Hypotonic IV fluids (D5W large-volume, hypotonic saline) at high oxytocin doses
Major
Oxytocin has intrinsic antidiuretic (ADH-like) activity. Continuous infusion ≥40–50 mU/min for prolonged periods with concurrent hypotonic fluid administration produces dilutional hyponatremia, water intoxication, seizures, coma, death. Pitocin FDA label Warnings: 'Water intoxication with convulsions, which is caused by the inherent antidiuretic effect of oxytocin, is a serious complication that may occur if large doses (40 to 50 milliunits/minute) are infused for long periods.' PMID 1197156 (Schwartz 1975); PMID 21503353 (case report).
Prostaglandin uterotonics (dinoprostone, misoprostol)
Major
Additive uterotonic effect — risk of severe uterine hypertonus, uterine rupture, cervical laceration. Dinoprostone labeling lists concurrent oxytocics as a contraindication. Pitocin FDA label Precautions + Cervidil (dinoprostone) FDA label Contraindications: 'Dinoprostone is contraindicated in patients receiving intravenous oxytocic agents.' Misoprostol concurrent use also flagged.
Vasoconstrictors / sympathomimetic pressors (epinephrine, ephedrine, methoxamine — particularly with caudal block)
Major
Severe hypertension reported when oxytocin is given 3–4 hours after prophylactic vasoconstrictor administration in conjunction with caudal-block anesthesia. Additive vasopressor effects. Pitocin FDA label Precautions: 'Severe hypertension has been reported when oxytocin was given three to four hours following prophylactic administration of a vasoconstrictor in conjunction with caudal block anesthesia.'
Magnesium sulfate (preeclampsia/eclampsia tocolytic)
Moderate
Pharmacodynamic antagonism — magnesium relaxes uterine smooth muscle, opposing oxytocin's uterotonic effect. Concurrent use is common in obstetric care but requires dose titration on both sides; magnesium also potentiates hypotension risk. Pitocin label Precautions notes need for caution in patients receiving tocolytic agents; obstetric anesthesia literature (PMID 21724029) describes dose adjustments.
Other oxytocics (ergot alkaloids — methylergonovine, ergonovine)
Moderate
Additive uterotonic effect; concurrent or sequential use without monitoring risks uterine hyperstimulation, rupture, and severe hypertension (ergots are also pressors). Class-effect warning consistent with Pitocin label Indications/Usage restriction to controlled infusion settings. Methergine label warns against concurrent oxytocics.
QT-prolonging drugs (class IA/III antiarrhythmics, ondansetron, methadone)
Moderate
Oxytocin bolus has been associated with transient QT prolongation; coadministration with other QT-prolongers may compound risk of torsade de pointes, particularly with electrolyte disturbance from water intoxication. PMID 19608824 (Charbit et al. 2009, oxytocin and QT) and case-series literature. Not explicit in current Pitocin label but flagged in anesthesia society guidance.
MDMA / serotonergic agents (intranasal oxytocin context)
Monitor
MDMA elevates endogenous plasma oxytocin; concurrent exogenous intranasal oxytocin is additive. The clinical relevance is debated (oxytocin half-life is short and CNS penetration of IN oxytocin is modest), but combined-use studies have been performed in research settings. Kirkpatrick et al. 2014, Psychoneuroendocrinology (PMID 24448644): 'Plasma oxytocin concentrations following MDMA or intranasal oxytocin in humans.' Compounded intranasal oxytocin is off-label; this is for research-context only.
Cerebrolysin 4 interactions
MAO inhibitors (phenelzine, tranylcypromine, selegiline, rasagiline, isocarboxazid)
Major
Additive central monoaminergic effects. High-dose MAOI + high-dose Cerebrolysin (≥30 mL) has been reported to increase blood pressure — consistent with augmented monoamine accumulation. Risk of hypertensive crisis. Cerebrolysin Treatment Handbook 2023 (EVER Neuro Pharma) Section 5: 'Special attention should be given to possible additive effects when used in conjunction with anti-depressants or MAO inhibitors. High doses of MAO inhibitors in combination with higher dosages of Cerebrolysin (≥ 30 ml) have been reported to increase blood pressure.'
Antidepressants (SSRIs — sertraline, fluoxetine; SNRIs — venlafaxine, duloxetine; TCAs — amitriptyline)
Moderate
Cerebrolysin's neuroactive peptide fraction has documented effects on monoamine neurotransmission. EMA-region prescribing info advises lowering antidepressant dose during concomitant therapy to avoid additive serotonergic / noradrenergic effects. Cerebrolysin Treatment Handbook 2023 Section 5: 'In such cases, it is recommended that the dose of the anti-depressant is lowered, although it is important to clarify whether it is safe to do so from a psychiatric perspective.'
Balanced amino acid / parenteral nutrition solutions (TPN)
Moderate
Physical / pharmaceutical incompatibility — Cerebrolysin must not be mixed in a single infusion with neutral amino acid solutions due to risk of precipitation, pH shift, and loss of biological activity. Cerebrolysin Treatment Handbook 2023 Section 2 (Instructions for Use): 'Cerebrolysin can be used with other pharmacological agent but not be mixed in a single infusion.' EMA SmPC Section 6.2 (Incompatibilities) lists balanced amino acid solutions.
Lipid-containing infusion solutions / parenteral lipids (Intralipid)
Minor
Physical incompatibility on co-infusion. Cerebrolysin should be diluted only in 0.9% sodium chloride, Ringer's, or 5% glucose — not in lipid-based solutions. Cerebrolysin Treatment Handbook 2023 Section 3.1 (Infusion): 'Dilution has to be prepared with the suggested standard infusion solutions e.g. 0.9% sodium chloride solution, Ringer's solution, 5% Glucose.'
N-Acetyl Selank Amidate 2 interactions
GABAergic CNS depressants (benzodiazepines, Z-drugs, gabapentinoids, alcohol)
Monitor
Selank modulates GABA receptor binding sites and GABAergic gene expression without acting as a direct GABA agonist. Theoretical additive sedation or anxiolysis when combined with classical GABAergic depressants; not characterized in human trials. Kost et al., GABAergic gene expression after Selank (ResearchGate 295186484). No human DDI data; classified 'monitor' rather than 'moderate' given the absence of receptor-agonism evidence.
Opioid analgesics and enkephalin-modulating agents
Monitor
Selank prolongs enkephalin half-life by inhibiting enkephalinase; theoretical augmentation of opioid effects or enkephalin-dependent stress responses. Mechanistic — derived from the Russian enkephalin half-life literature on Selank. No N-Acetyl Selank human DDI data exists.
Triptorelin (Trelstar) 6 interactions
Class IA antiarrhythmics (quinidine, procainamide, disopyramide)
Major
Androgen deprivation prolongs QTc; concurrent class IA agents (which themselves prolong QT) compound the risk of torsade de pointes. Trelstar FDA label Section 5.5 (Warnings): 'Androgen deprivation therapy may prolong the QT interval. Consider whether the benefits of androgen deprivation therapy outweigh the potential risks in patients with congenital long QT syndrome, electrolyte abnormalities, or congestive heart failure and in patients taking Class IA or Class III antiarrhythmic medications.'
Class III antiarrhythmics (amiodarone, sotalol, dofetilide, ibutilide)
Major
Same as Class IA — additive QTc prolongation on top of ADT-mediated baseline QTc lengthening; torsade risk. Trelstar FDA label Section 5.5 (Warnings). PMID 29202101 (Hu et al., J Endocr Soc 2018) — ADT prolongs QTc in prostate cancer.
Hyperprolactinemic drugs (antipsychotics — risperidone, haloperidol; metoclopramide; some SSRIs)
Moderate
Hyperprolactinemia downregulates pituitary GnRH receptors, blunting triptorelin's pharmacodynamic effect on LH/FSH suppression. Loss of efficacy is the concern, not toxicity. Trelstar FDA label Section 7 (Drug Interactions): 'In the absence of relevant data and as a precaution, hyperprolactinemic drugs should not be used concomitantly with triptorelin since hyperprolactinemia reduces the number of pituitary GnRH receptors.'
Methadone, ondansetron, fluoroquinolones, macrolides (azithromycin, clarithromycin), other QT-prolongers
Moderate
Same mechanism — additive QTc effect with ADT-induced QTc prolongation. Risk amplified by electrolyte derangement (hypokalemia, hypomagnesemia). Trelstar Section 5.5 generalizes to QT-prolongers; PMID 32382435 (torsades with ADT case series).
Diabetes medications (insulin, metformin, sulfonylureas)
Monitor
ADT (including triptorelin) increases insulin resistance, fasting glucose, HbA1c, and diabetes incidence. Diabetic patients may need antidiabetic dose intensification. Trelstar FDA label Section 5.4: 'Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving gonadotropin-releasing hormone (GnRH) agonists. Monitor blood glucose and/or glycosylated hemoglobin (HbA1c) periodically.'
Drugs that lower seizure threshold (bupropion, tramadol, clozapine)
Monitor
Post-marketing reports of convulsions with GnRH agonists, including in patients without prior seizure history. Coadministration of seizure-threshold-lowering agents may compound risk. Trelstar FDA label Section 5.6 (Warnings — Convulsions): 'There have been post-marketing reports of convulsions in patients receiving TRELSTAR. These included patients with and without a history of seizures, epilepsy, cerebrovascular disorders, central nervous system anomalies or tumors, and patients on concomitant medications that have been associated with convulsions such as bupropion and SSRIs.'
Hexarelin 4 interactions
Somatostatin analogs (octreotide, lanreotide, pasireotide)
Major
Direct physiologic antagonism of GH release; somatostatin abolishes hexarelin's GH-releasing effect. Class effect for ghrelin-receptor agonists. Springer doi:10.1007/978-1-4615-7886-4_18.
Dopamine agonists (cabergoline, bromocriptine)
Moderate
Hexarelin transiently elevates prolactin via a dose-dependent mechanism (Massoud 1996); dopamine agonists used to suppress prolactin may have their effect partially counteracted, complicating prolactinoma management. Massoud AF et al, J Clin Endocrinol Metab 1996;81(12):4338-4341 (PMID 8954038) — hexarelin dose-response prolactin elevation. Frieboes RM et al, J Sleep Res 2004;13(2):133-141 (PMID 15177700).
Glucocorticoids (prednisone, dexamethasone, hydrocortisone)
Moderate
Two distinct mechanisms: (1) chronic pharmacologic glucocorticoids blunt GH release from hexarelin via somatostatinergic tone; (2) hexarelin transiently elevates ACTH and endogenous cortisol via AVP-mediated HPA activation, potentially confounding diagnostic glucocorticoid suppression testing. Korbonits M et al, J Clin Endocrinol Metab 1999;84(7):2489-2495 (PMID 10404825) — hexarelin HPA activation via AVP. Arvat E et al, J Clin Endocrinol Metab 1997;82(8):2585-2590 (PMID 9253314). Mazziotti & Giustina, Nat Rev Endocrinol 2013;9(5):265-276 (PMID 23438833).
Insulin and oral hypoglycemics
Moderate
Chronic GH/IGF-1 elevation reduces insulin sensitivity (class effect for GH secretagogues). Hexarelin's additional cortisol elevation may compound the diabetogenic effect vs more selective agonists like ipamorelin. GH-glucose axis: Mazziotti & Giustina, Nat Rev Endocrinol 2013;9(5):265-276 (PMID 23438833). Hexarelin cortisol elevation: Arvat 1997 (PMID 9253314), Massoud 1996 (PMID 8954038).
GHRP-2 4 interactions
Somatostatin analogs (octreotide, lanreotide, pasireotide)
Major
Direct antagonism of GH release downstream of the ghrelin receptor. Class effect for ghrelin-receptor agonists. Springer doi:10.1007/978-1-4615-7886-4_18.
Dopamine agonists (cabergoline, bromocriptine)
Moderate
GHRP-2 transiently elevates prolactin (class effect shared with GHRP-6 and hexarelin); dopamine agonists used for prolactin suppression may have efficacy partially counteracted. Garcia JM, Polvino WJ — pharmacodynamics of ghrelin agonists; reviewed in 'The Human Experience With Ghrelin Administration', PMC3644599. Class effect for non-selective GHRPs (contrast with ipamorelin, Raun 1998 PMID 9849822).
Glucocorticoids (prednisone, dexamethasone, hydrocortisone)
Moderate
GHRP-2 raises ACTH and cortisol via central HPA mechanisms (class effect with hexarelin/GHRP-6); concurrent exogenous glucocorticoid plus GHRP-2 can produce additive cortisol burden, particularly in stress, sepsis, or adrenal insufficiency reversal scenarios. Conversely chronic glucocorticoids blunt GH response. Class effect: Korbonits M et al, J Clin Endocrinol Metab 1999;84(7):2489-2495 (PMID 10404825). Mazziotti & Giustina, Nat Rev Endocrinol 2013;9(5):265-276 (PMID 23438833). Ghrelin/GHRP-2 ACTH literature: PMC3644599.
Insulin and oral hypoglycemics
Moderate
GH/IGF-1 elevation reduces insulin sensitivity; ghrelin agonism additionally suppresses post-prandial insulin secretion (acute ghrelin pharmacology), worsening glucose tolerance vs more selective agonists. Mazziotti & Giustina, Nat Rev Endocrinol 2013;9(5):265-276 (PMID 23438833). Ghrelin glucose effects: PMC3644599.
GHRP-6 5 interactions
Somatostatin analogs (octreotide, lanreotide, pasireotide)
Major
Direct physiologic antagonism — somatostatin blocks GH release downstream of the ghrelin receptor. Class effect; Springer doi:10.1007/978-1-4615-7886-4_18.
Dopamine agonists (cabergoline, bromocriptine)
Moderate
GHRP-6 transiently elevates prolactin (consistently demonstrated in healthy volunteers and in type 1 diabetes cohorts); dopamine agonist effect partially counteracted. Class effect for non-selective GHRPs; reviewed in 'The Human Experience With Ghrelin Administration', PMC3644599. Original Bowers work — Bowers CY et al, Endocrinology 1984;114(5):1537-1545 (PMID 6714155).
Glucocorticoids (prednisone, dexamethasone, hydrocortisone)
Moderate
GHRP-6 stimulates ACTH and cortisol release in parallel with ghrelin; concurrent exogenous glucocorticoids can produce additive cortisol load. Conversely, chronic pharmacologic glucocorticoids suppress GH response. Korbonits M et al, J Clin Endocrinol Metab 1999;84(7):2489-2495 (PMID 10404825). Mazziotti & Giustina, Nat Rev Endocrinol 2013;9(5):265-276 (PMID 23438833). PMC3644599 ghrelin/cortisol literature.
Insulin and oral hypoglycemics
Moderate
Ghrelin agonism suppresses post-prandial insulin secretion acutely; chronic GH/IGF-1 elevation drives insulin resistance. Net effect impairs glucose control in T1DM/T2DM patients on insulin or oral hypoglycemics. Ghrelin glucose effects: PMC3644599. GH-glucose axis: Mazziotti & Giustina, PMID 23438833.
Appetite-modulating drugs (GLP-1 agonists semaglutide/tirzepatide/liraglutide, antipsychotics, anorexiants)
Minor
GHRP-6 is a potent appetite stimulant via ghrelin-receptor agonism (more so than GHRP-2 or ipamorelin); this directly counteracts the appetite-suppressing action of GLP-1 agonists and other anorexiants, and may exacerbate antipsychotic-induced weight gain. Ghrelin/GHRP-6 orexigenic effect well documented; reviewed in PMC3644599 'The Human Experience With Ghrelin Administration'. Original ghrelin appetite literature: Wren AM et al, J Clin Endocrinol Metab 2001;86(12):5992 (PMID 11739476).
IGF-1 LR3 7 interactions
Insulin and insulin analogs (regular, aspart, lispro, glargine, detemir, degludec)
Major
IGF-1 LR3 binds insulin receptors with ~10% the affinity of insulin and binds IGF-1 receptors with high affinity; it suppresses hepatic glucose output and stimulates peripheral glucose uptake. Concurrent insulin produces severe additive hypoglycemia, especially within the first month of IGF-1 LR3 use before IGF-1-mediated insulin secretion suppression compensates. Increlex FDA label (NDA 021839) — Warnings 5.1 Hypoglycemia, Drug Interactions 7.1 Insulin and other anti-diabetic agents. Mecasermin monograph (Drugs.com Mecasermin Monograph for Professionals).
Meglitinides (repaglinide, nateglinide)
Major
Insulin secretagogue effect plus IGF-1 LR3 direct glucose disposal — additive hypoglycemia risk equivalent to sulfonylureas. Increlex FDA label Drug Interactions class warning, NDA 021839.
Sulfonylureas (glipizide, glyburide, glimepiride)
Major
Sulfonylureas drive endogenous insulin secretion which adds to IGF-1 LR3's insulin-receptor agonism, producing severe additive hypoglycemia. The IGF-1 LR3 effect persists ~20-30 hours per dose, making the interaction sustained. Increlex FDA label Drug Interactions 7.1 — anti-diabetic agents class warning, NDA 021839. Mecasermin DrugBank DB01277.
Glucocorticoids (prednisone, dexamethasone — supraphysiologic)
Moderate
Per Increlex label: pharmacologic anti-inflammatory steroid doses cause secondary IGF-1 deficiency and are themselves a contraindication for IGF-1 substitution therapy interpretation. Concurrent IGF-1 LR3 plus pharmacologic glucocorticoids creates conflicting metabolic effects (glucose dysregulation in both directions) and confounds dosing. Increlex FDA label — Indications/Limitations: 'not indicated for use in patients with secondary forms of IGFD, such as ... chronic treatment with pharmacologic doses of anti-inflammatory steroids.' NDA 021839.
Macimorelin (GH stimulation diagnostic agent)
Moderate
IGF-1 LR3 blunts the GH response to macimorelin (and other GH-stimulation diagnostics like insulin tolerance testing, arginine, glucagon) by suppressing endogenous GH secretion via negative feedback, impairing diagnostic accuracy. Mecasermin Medscape interactions entry; mechanism is established negative feedback of IGF-1 on pituitary GH release.
Recombinant human growth hormone (somatropin, somatrogon)
Moderate
Per Increlex label: IGF-1 products are NOT indicated as substitutes for GH therapy. Concurrent GH plus IGF-1 LR3 can produce supraphysiologic IGF-1 levels with increased risk of acromegalic features, sleep apnea, and tonsillar hypertrophy. Endogenous IGF-1 generation from GH is on top of exogenous IGF-1 LR3. Increlex FDA label — Indications and Limitations of Use, NDA 021839: 'INCRELEX is not a substitute to GH for approved GH indications.' Mecasermin monograph (Drugs.com).
Levothyroxine (and thyroid hormone replacement)
Minor
IGF-1 LR3 may modestly alter thyroid hormone metabolism and binding (class effect for GH/IGF-1 axis activation); thyroid hormone replacement doses may need monitoring during initiation or dose changes. Class effect for GH/IGF-1 axis manipulation. GH-thyroid axis interaction reviewed in Mazziotti & Giustina, PMID 23438833.
Kisspeptin-10 2 interactions
GnRH analogs (leuprolide, goserelin, triptorelin) and GnRH antagonists (cetrorelix, ganirelix, degarelix)
Moderate
Kisspeptin acts upstream of GnRH neurons; concomitant GnRH-pathway pharmacotherapy (agonists causing downregulation, antagonists blocking GnRH receptors) will either negate or unpredictably modify the LH/FSH response to kisspeptin. Mechanistic interaction at the same axis; co-use defeats the purpose of either drug. Skorupskaite K et al., 'The kisspeptin-GnRH pathway in human reproductive health and disease,' Hum Reprod Update 2014;20(4):485-500 (PMC4063702).
Opioids (morphine, oxycodone, fentanyl, methadone)
Moderate
Opioids suppress hypothalamic GnRH release, which is the downstream effector that kisspeptin stimulates. Rodent studies show morphine attenuates the testosterone response to central kisspeptin injection. Clinically, opioid use can blunt expected kisspeptin-induced LH/testosterone rises. Co-administration is unlikely to be acutely dangerous but reduces the pharmacodynamic effect of kisspeptin. Khajehpour L et al., 'Morphine Attenuates Testosterone Response to Central Injection of Kisspeptin in Male Rats,' (PMC4107696). Naderi M, Nasri S, 'Interactions of Morphine and Peptide 234 on Mean Plasma Testosterone Concentration,' Int J Endocrinol Metab 2014;12(2):e15447 (PMC3969002).
Larazotide Acetate (AT-1001 / oral) 1 interaction
Oral medications taken concurrently (timing-dependent)
Minor
Larazotide is administered orally pre-meal to act locally on intestinal tight junctions. The clinical trial protocol specified dosing 15 minutes before meals to maximize local effect; larazotide itself has minimal systemic absorption. Because the drug acts at the intestinal lumen on tight junctions, theoretical timing-related effects on co-administered oral drug absorption are plausible but unproven in clinical pharmacology studies. Trial protocols did not require separation from other oral drugs. Larazotide Phase 3 CeDLara trial NCT03569007 (9 Meters Biopharma); Khaleghi S et al., 'The potential utility of tight junction regulation in celiac disease' Ther Adv Gastroenterol 2016. Trial protocol summarized on BeyondCeliac.org and Wikipedia Larazotide entry.
Foundayo (Orforglipron) 12 interactions
General anesthesia / deep sedation (preoperative aspiration risk)
Major
Delayed gastric emptying — class effect. Once-daily oral dosing means recent residual drug exposure on day of procedure. FDA Foundayo label §5.x (perioperative aspiration warning). ASA 2023 + 2024 multisociety guidance: hold once-daily Foundayo on day of elective procedures requiring general anesthesia or deep sedation. Source: FDA Foundayo PI 2026 §5.x; PMID: 39550027.
Insulin
Major
Additive hypoglycemia. GLP-1RA glucose-dependent insulin secretion plus exogenous insulin. FDA Foundayo label §5.x and §7. Reduce insulin dose at Foundayo initiation. Source: FDA Foundayo PI 2026.
Oral hormonal contraceptives (ethinyl estradiol / progestins)
Major
Orforglipron reduced ethinyl estradiol exposure. Combined with delayed gastric emptying, contraceptive efficacy may be reduced. FDA Foundayo label §7.3 and §8.3. Switch to non-oral contraception, OR add a barrier method for 4 weeks after Foundayo initiation AND for 4 weeks after each dose escalation. Source: FDA Foundayo PI 2026 §7.3, §8.3.
Other GLP-1 receptor agonists or incretin agonists (semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide, retatrutide)
Major
Duplicate therapy — no efficacy benefit, additive GI and aspiration risk. FDA Foundayo label — not studied in combination. Use one GLP-1RA / incretin agent at a time. Source: FDA Foundayo PI 2026.
Simvastatin
Major
Orforglipron substantially increased exposure to the active metabolite simvastatin acid, regardless of dosing time-separation. Rhabdomyolysis risk rises with simvastatin acid exposure. FDA Foundayo label §7.2 and §12.3 Table 4. Do NOT exceed simvastatin 20 mg once daily when used concomitantly with Foundayo. Source: FDA Foundayo PI 2026 §7.2.
Strong CYP3A4 inducers (rifampin, rifabutin, carbamazepine, phenytoin, phenobarbital, primidone, enzalutamide, mitotane, St. John's Wort, apalutamide)
Major
Strong CYP3A4 inducers reduce orforglipron exposure. Carbamazepine reduced orforglipron AUC by approximately 82% in the DDI study (NCT06370728). FDA Foundayo label §7.1 and §12.3 Table 5. AVOID coadministration. Loss of glycemic and weight-loss efficacy expected. Source: FDA Foundayo PI 2026 §7.1; NCT06370728.
Strong CYP3A4 inhibitors that also inhibit OATP1B (clarithromycin, telithromycin, itraconazole, ketoconazole, voriconazole, posaconazole, cobicistat, ritonavir, nelfinavir)
Major
Orforglipron is primarily metabolized by hepatic CYP3A4. Strong CYP3A4 inhibitors that also inhibit OATP1B raise orforglipron exposure approximately 3.5-fold, dramatically increasing risk of GI adverse events and severe hypoglycemia when combined with insulin/sulfonylurea. FDA Foundayo label §7.1 and §12.3 Table 4. AVOID coadministration. If unavoidable, maximum Foundayo dosage is 9 mg once daily during concomitant use with a strong CYP3A4 inhibitor. Source: FDA Foundayo PI 2026 (220934Orig1s000) §7.1.
Sulfonylureas (glipizide, glyburide, glimepiride)
Major
Additive hypoglycemia — class effect for GLP-1RAs. FDA Foundayo label §7. Reduce sulfonylurea dose at Foundayo initiation. Source: FDA Foundayo PI 2026.
Drugs causing pancreatitis (valproate, azathioprine, didanosine, pentamidine, high-dose corticosteroids, DPP-4 inhibitors) and alcohol
Moderate
Additive risk of acute pancreatitis — GLP-1RA class effect. FDA Foundayo label §5.x (pancreatitis precaution). Discontinue if pancreatitis suspected. Source: FDA Foundayo PI 2026.
Moderate CYP3A4 inducers (efavirenz, etravirine, modafinil, bosentan, dabrafenib)
Moderate
Reduced orforglipron exposure of lesser magnitude than strong inducers. FDA Foundayo label §7.1. Monitor Foundayo effectiveness and escalate dose as tolerated to compensate, within standard dose ladder. Source: FDA Foundayo PI 2026 §7.1.
Narrow-therapeutic-index oral drugs (warfarin, digoxin, levothyroxine, phenytoin, lithium, cyclosporine, tacrolimus)
Moderate
Delayed gastric emptying may alter rate of oral absorption. FDA Foundayo label §7.3. Monitor as clinically indicated. Source: FDA Foundayo PI 2026 §7.3.
Other statins — rosuvastatin, atorvastatin, pravastatin, pitavastatin
Monitor
No clinically relevant change in rosuvastatin or atorvastatin exposure in DDI studies. Pravastatin and pitavastatin not directly studied but transporter profile suggests low risk. FDA Foundayo label §12.3 Table 4. Rosuvastatin and atorvastatin are safer alternatives to simvastatin in patients on Foundayo. Source: FDA Foundayo PI 2026 §12.3.
Liraglutide (Victoza / Saxenda) 10 interactions
General anesthesia / deep sedation (preoperative aspiration risk)
Major
Delayed gastric emptying; class effect with postmarketing aspiration reports. ASA 2023 consensus: once-daily liraglutide should be held on the day of the procedure (longer hold than for once-weekly agents). Multisociety 2024 update (PMID: 39550027). Source: FDA Victoza PI 2025; ASA Consensus 2023.
Insulin
Major
Additive hypoglycemia. LEADER and SCALE trials showed elevated hypoglycemia rates with combined insulin + liraglutide. FDA Victoza label §5.4 and §7.1; FDA Saxenda label §5.x. Reduce insulin dose at liraglutide initiation; monitor glucose. Source: FDA Victoza PI 2025 (022341s046).
Sulfonylureas (glipizide, glyburide, glimepiride)
Major
Additive hypoglycemia by combined glucose-independent and glucose-dependent insulin secretion plus delayed gastric emptying. FDA Victoza label §7.1. Consider sulfonylurea dose reduction at liraglutide initiation. Source: FDA Victoza PI 2025.
Drugs causing pancreatitis (valproate, azathioprine, didanosine, pentamidine, high-dose corticosteroids, DPP-4 inhibitors) and alcohol
Moderate
Additive risk of acute pancreatitis. Acute pancreatitis reported in LEADER trial on liraglutide. FDA Victoza label §5.4 and Saxenda §5.x. Discontinue if pancreatitis suspected. Alcohol moderation advised. Source: FDA Victoza PI 2025 §5.4.
Griseofulvin (and other low-solubility, highly lipophilic oral drugs)
Moderate
Single liraglutide dose increased griseofulvin Cmax 37% but did not change AUC. The Cmax change was attributed to altered gastric emptying. FDA Victoza label §12.3 and §7.2. Source: FDA Victoza PI 2025 §12.3.
Oral hormonal contraceptives (ethinyl estradiol / levonorgestrel)
Moderate
Single liraglutide dose decreased ethinyl estradiol Cmax 12% and levonorgestrel Cmax 13%, with Tmax delayed 1.5 hours. AUC for both was reduced by less than 20%. FDA Victoza label §12.3. Effect deemed not clinically significant for contraceptive efficacy with subQ liraglutide, contrasting with the higher-magnitude effect on tirzepatide. No barrier method requirement on liraglutide. Source: FDA Victoza PI 2025 §12.3.
Acetaminophen (paracetamol)
Monitor
Single 1.8 mg liraglutide dose decreased acetaminophen Cmax 31% and delayed Tmax by 15 min. Total AUC unchanged. FDA Victoza label §12.3 PK table. Clinical significance low for routine analgesic use. Source: FDA Victoza PI 2025 §12.3.
Atorvastatin
Monitor
Single liraglutide dose decreased atorvastatin Cmax 38% and delayed Tmax. AUC unchanged. FDA Victoza label §12.3. No dose adjustment needed; effect on chronic dosing minimal. Source: FDA Victoza PI 2025 §12.3.
Digoxin
Monitor
Single liraglutide dose decreased digoxin AUC by 16% and Cmax by 31%, with Tmax delayed by 1 hour. Effect attenuates with chronic dosing. FDA Victoza label §12.3. No dose adjustment required but consider digoxin level monitoring during severe GI adverse events. Source: FDA Victoza PI 2025 §12.3.
Lisinopril
Monitor
Single liraglutide dose decreased lisinopril Cmax 27% and delayed Tmax by 6 hours. AUC unchanged. FDA Victoza label §12.3. No dose adjustment but monitor BP response after liraglutide initiation. Source: FDA Victoza PI 2025 §12.3.
Pielotax (A-9 Kidney Peptide Bioregulator) 4 interactions
Beef / gelatin / bovine collagen allergy
Major
Patients with known bovine protein allergy have theoretical anaphylaxis / sensitization risk from bovine kidney extract. Not a drug interaction — contraindication.
ACE inhibitors and ARBs (lisinopril, losartan, etc.)
Monitor
Common co-prescription in CKD patients who might consider Pielotax. No published interaction data. Renal-modulating agents + renal peptide extract has unknown net effect. No formal DDI study.
Immunosuppressants (tacrolimus, cyclosporine, sirolimus, everolimus, corticosteroids)
Monitor
Theoretical concern — foreign bovine protein exposure in transplant recipients or autoimmune patients. No published DDI study. No formal drug-drug interaction studies published for Pielotax. Class caution based on mechanism only.
SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin)
Monitor
Same CKD-population overlap. No interaction data. No formal DDI study.
Semaglutide (oral — Rybelsus) 9 interactions
General anesthesia / deep sedation (preoperative aspiration risk)
Major
Delayed gastric emptying produces residual gastric contents despite NPO; rare postmarketing reports of pulmonary aspiration. FDA class labeling added 2024. ASA 2023 consensus: consider holding once-daily oral semaglutide on day of elective procedure. Multisociety 2024 update (PMID: 39550027) emphasizes shared decision-making. Source: FDA Rybelsus PI 2024; ASA Consensus 2023.
Insulin (basal and prandial)
Major
Additive hypoglycemia risk in patients with type 2 diabetes. Reduce insulin dose at semaglutide initiation. FDA Rybelsus label §5.4 and §7.1; FDA Oral Wegovy label. Titrate insulin based on glucose monitoring. Source: FDA Rybelsus PI 2024 (213051s018); FDA Oral Wegovy PI 2025 (218316).
Other GLP-1 receptor agonists / incretin agonists (tirzepatide, liraglutide, dulaglutide, exenatide, retatrutide, orforglipron, injectable semaglutide)
Major
Duplicate therapy — no additional efficacy, additive GI and aspiration risk. FDA Rybelsus / Oral Wegovy labels. Use only one incretin agent at a time. Source: FDA Rybelsus PI 2024.
Sulfonylureas (glipizide, glyburide, glimepiride)
Major
Additive hypoglycemia via combined insulin-secretagogue effect plus delayed gastric emptying. FDA Rybelsus label §7.1. Consider sulfonylurea dose reduction at semaglutide initiation. Source: FDA Rybelsus PI 2024.
Drugs altering gastric pH (PPIs: omeprazole, esomeprazole, pantoprazole; H2 blockers: famotidine; antacids)
Moderate
Oral semaglutide absorption depends on transient gastric pH change from SNAC co-formulation. Omeprazole 40 mg daily increased semaglutide AUC modestly in DDI study. FDA Rybelsus label §12.3. Take Rybelsus/Oral Wegovy per its labeling (empty stomach, ≤120 mL water, then 30-min fast); PPI use does not require semaglutide dose adjustment but counsel on strict timing. Source: FDA Rybelsus PI 2024 §12.3.
Drugs causing pancreatitis (valproate, azathioprine, didanosine, pentamidine, high-dose corticosteroids, DPP-4 inhibitors)
Moderate
Additive risk of acute pancreatitis. SUSTAIN and STEP trials reported pancreatitis cases on semaglutide. FDA Rybelsus and Oral Wegovy labels §5.3. Discontinue semaglutide if pancreatitis suspected. Source: FDA Rybelsus PI 2024 §5.3.
Levothyroxine
Moderate
Levothyroxine total exposure (AUC) increased 33% (90% CI 125-142%) when coadministered with oral semaglutide. Mechanism is altered gastric absorption window related to SNAC co-formulation. FDA Rybelsus label §7.2 and §12.3. Monitor TSH 6-8 weeks after reaching maintenance semaglutide dose; adjust levothyroxine dose as needed. Subcutaneous Ozempic/Wegovy do NOT show this PK effect. Source: FDA Rybelsus PI 2024 (213051s018).
Oral medications with narrow therapeutic index (digoxin, phenytoin, lithium, cyclosporine, tacrolimus)
Moderate
Delayed gastric emptying plus the gastric-pH absorption-window effect from SNAC co-formulation alter rate and occasionally extent of oral absorption. FDA Rybelsus label §7.2. Take Rybelsus/Oral Wegovy at least 30 minutes before any other oral medication, food, or liquid. Monitor drug levels for narrow-TI drugs. Source: FDA Rybelsus PI 2024 §2.1, §7.2.
Alcohol (ethanol)
Monitor
Additive GI adverse effects; potential additive hypoglycemia when combined with insulin or sulfonylureas; pancreatitis risk factor. FDA Rybelsus label §5.3 (pancreatitis precaution). Advise moderation. Source: FDA Rybelsus PI 2024.
Semaglutide (oral — Wegovy) 9 interactions
General anesthesia / deep sedation (preoperative aspiration risk)
Major
Delayed gastric emptying produces residual gastric contents despite NPO; rare postmarketing reports of pulmonary aspiration. FDA class labeling added 2024. ASA 2023 consensus: consider holding once-daily oral semaglutide on day of elective procedure. Multisociety 2024 update (PMID: 39550027) emphasizes shared decision-making. Source: FDA Rybelsus PI 2024; ASA Consensus 2023.
Insulin (basal and prandial)
Major
Additive hypoglycemia risk in patients with type 2 diabetes. Reduce insulin dose at semaglutide initiation. FDA Rybelsus label §5.4 and §7.1; FDA Oral Wegovy label. Titrate insulin based on glucose monitoring. Source: FDA Rybelsus PI 2024 (213051s018); FDA Oral Wegovy PI 2025 (218316).
Other GLP-1 receptor agonists / incretin agonists (tirzepatide, liraglutide, dulaglutide, exenatide, retatrutide, orforglipron, injectable semaglutide)
Major
Duplicate therapy — no additional efficacy, additive GI and aspiration risk. FDA Rybelsus / Oral Wegovy labels. Use only one incretin agent at a time. Source: FDA Rybelsus PI 2024.
Sulfonylureas (glipizide, glyburide, glimepiride)
Major
Additive hypoglycemia via combined insulin-secretagogue effect plus delayed gastric emptying. FDA Rybelsus label §7.1. Consider sulfonylurea dose reduction at semaglutide initiation. Source: FDA Rybelsus PI 2024.
Drugs altering gastric pH (PPIs: omeprazole, esomeprazole, pantoprazole; H2 blockers: famotidine; antacids)
Moderate
Oral semaglutide absorption depends on transient gastric pH change from SNAC co-formulation. Omeprazole 40 mg daily increased semaglutide AUC modestly in DDI study. FDA Rybelsus label §12.3. Take Rybelsus/Oral Wegovy per its labeling (empty stomach, ≤120 mL water, then 30-min fast); PPI use does not require semaglutide dose adjustment but counsel on strict timing. Source: FDA Rybelsus PI 2024 §12.3.
Drugs causing pancreatitis (valproate, azathioprine, didanosine, pentamidine, high-dose corticosteroids, DPP-4 inhibitors)
Moderate
Additive risk of acute pancreatitis. SUSTAIN and STEP trials reported pancreatitis cases on semaglutide. FDA Rybelsus and Oral Wegovy labels §5.3. Discontinue semaglutide if pancreatitis suspected. Source: FDA Rybelsus PI 2024 §5.3.
Levothyroxine
Moderate
Levothyroxine total exposure (AUC) increased 33% (90% CI 125-142%) when coadministered with oral semaglutide. Mechanism is altered gastric absorption window related to SNAC co-formulation. FDA Rybelsus label §7.2 and §12.3. Monitor TSH 6-8 weeks after reaching maintenance semaglutide dose; adjust levothyroxine dose as needed. Subcutaneous Ozempic/Wegovy do NOT show this PK effect. Source: FDA Rybelsus PI 2024 (213051s018).
Oral medications with narrow therapeutic index (digoxin, phenytoin, lithium, cyclosporine, tacrolimus)
Moderate
Delayed gastric emptying plus the gastric-pH absorption-window effect from SNAC co-formulation alter rate and occasionally extent of oral absorption. FDA Rybelsus label §7.2. Take Rybelsus/Oral Wegovy at least 30 minutes before any other oral medication, food, or liquid. Monitor drug levels for narrow-TI drugs. Source: FDA Rybelsus PI 2024 §2.1, §7.2.
Alcohol (ethanol)
Monitor
Additive GI adverse effects; potential additive hypoglycemia when combined with insulin or sulfonylureas; pancreatitis risk factor. FDA Rybelsus label §5.3 (pancreatitis precaution). Advise moderation. Source: FDA Rybelsus PI 2024.
No matches. Try a different search.
Peptides with limited published interaction data:
Many research peptides have not been studied in formal pharmacokinetic interaction trials. Always consult your prescriber before combining with prescription medications.